VRAX Fundamental Analysis - VIRAX BIOLABS GROUP LTD

Name: VIRAX BIOLABS GROUP LTD (VRAX) Stock
Brand: VIRAX BIOLABS GROUP LTD
Rating: 1.5 (3 reviews)

Fundamental Rating

Overall VRAX gets a fundamental rating of 3 out of 10. We evaluated VRAX against 101 industry peers in the Health Care Providers & Services industry. While VRAX seems to be doing ok healthwise, there are quite some concerns on its profitability. VRAX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year VRAX has reported negative net income.

VRAX had a negative operating cash flow in the past year.

VRAX had negative earnings in each of the past 5 years.

In the past 5 years VRAX always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of VRAX (-94.31%) is worse than 95.05% of its industry peers.

VRAX has a worse Return On Equity (-106.41%) than 76.24% of its industry peers.

		Industry Rank	Sector Rank
ROA	-94.31%
ROE	-106.41%
ROIC	N/A

ROA(3y)-90.9%

ROA(5y)-1063.54%

ROE(3y)-97.23%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VRAX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for VRAX has been increased compared to 1 year ago.

VRAX has less shares outstanding than it did 5 years ago.

VRAX has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 0.17, we must say that VRAX is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of 0.17, VRAX is not doing good in the industry: 77.23% of the companies in the same industry are doing better.

A Debt/Equity ratio of 0.06 indicates that VRAX is not too dependend on debt financing.

VRAX has a better Debt to Equity ratio (0.06) than 79.21% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.06
Debt/FCF	N/A
Altman-Z	0.17

ROIC/WACCN/A

WACC11.12%

2.3 Liquidity

VRAX has a Current Ratio of 7.27. This indicates that VRAX is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of VRAX (7.27) is better than 97.03% of its industry peers.

VRAX has a Quick Ratio of 7.13. This indicates that VRAX is financially healthy and has no problem in meeting its short term obligations.

With an excellent Quick ratio value of 7.13, VRAX belongs to the best of the industry, outperforming 97.03% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	7.27
Quick Ratio	7.13

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.82% over the past year.

Looking at the last year, VRAX shows a very negative growth in Revenue. The Revenue has decreased by -95.91% in the last year.

Measured over the past years, VRAX shows a very negative growth in Revenue. The Revenue has been decreasing by -42.47% on average per year.

EPS 1Y (TTM)50.82%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%55.62%

Revenue 1Y (TTM)-95.91%

Revenue growth 3YN/A

Revenue growth 5Y-42.47%

Sales Q2Q%-98.25%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

VRAX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.04% yearly.

EPS Next Y166.67%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year66.97%

Revenue Next 2Y-29.64%

Revenue Next 3Y-4.67%

Revenue Next 5Y16.04%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

VRAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

The Price/Forward Earnings ratio is 9.17, which indicates a very decent valuation of VRAX.

VRAX's Price/Forward Earnings ratio is rather cheap when compared to the industry. VRAX is cheaper than 93.07% of the companies in the same industry.

VRAX is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.42, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	9.17

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

VRAX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

VRAX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VIRAX BIOLABS GROUP LTD

NASDAQ:VRAX (11/21/2025, 8:04:53 PM)

After market: 0.3887 +0.01 (+3.93%)

0.374

-0.03 (-6.92%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)N/A N/A

Earnings (Next)12-13 2022-12-13/bmo

Inst Owners6.06%

Inst Owner ChangeN/A

Ins Owners9.73%

Ins Owner ChangeN/A

Market Cap1.62M

Revenue(TTM)6.40K

Net Income(TTM)-6.06M

AnalystsN/A

Price TargetN/A

Short Float %1.13%

Short Ratio0.17

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	9.17
P/S	253.62
P/FCF	N/A
P/OCF	N/A
P/B	0.28
P/tB	0.28
EV/EBITDA	N/A

EPS(TTM)-1.65

EYN/A

EPS(NY)0.04

Fwd EY10.91%

FCF(TTM)-1.19

FCFYN/A

OCF(TTM)-1.05

OCFYN/A

SpS0

BVpS1.31

TBVpS1.31

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-94.31%
ROE	-106.41%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-90.9%

ROA(5y)-1063.54%

ROE(3y)-97.23%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.06
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	175.86%
Cap/Sales	9435.94%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.27
Quick Ratio	7.13
Altman-Z	0.17

F-Score2

WACC11.12%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)4134.9%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)50.82%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%55.62%

EPS Next Y166.67%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-95.91%

Revenue growth 3YN/A

Revenue growth 5Y-42.47%

Sales Q2Q%-98.25%

Revenue Next Year66.97%

Revenue Next 2Y-29.64%

Revenue Next 3Y-4.67%

Revenue Next 5Y16.04%

EBIT growth 1Y-0.93%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year161.03%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y30.28%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y26.95%

OCF growth 3YN/A

OCF growth 5YN/A

VIRAX BIOLABS GROUP LTD / VRAX FAQ

Can you provide the ChartMill fundamental rating for VIRAX BIOLABS GROUP LTD?

ChartMill assigns a fundamental rating of 3 / 10 to VRAX.

Can you provide the valuation status for VIRAX BIOLABS GROUP LTD?

ChartMill assigns a valuation rating of 3 / 10 to VIRAX BIOLABS GROUP LTD (VRAX). This can be considered as Overvalued.

What is the profitability of VRAX stock?

VIRAX BIOLABS GROUP LTD (VRAX) has a profitability rating of 0 / 10.

Can you provide the expected EPS growth for VRAX stock?

The Earnings per Share (EPS) of VIRAX BIOLABS GROUP LTD (VRAX) is expected to grow by 166.67% in the next year.

VIRAX BIOLABS GROUP LTD (VRAX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

VIRAX BIOLABS GROUP LTD / VRAX FAQ

Can you provide the ChartMill fundamental rating for VIRAX BIOLABS GROUP LTD?

Can you provide the valuation status for VIRAX BIOLABS GROUP LTD?

What is the profitability of VRAX stock?

Can you provide the expected EPS growth for VRAX stock?